Practical considerations in the use of regorafenib in metastatic colorectal cancer

Fotios Loupakis, Lorenzo Antonuzzo, Jean Baptiste Bachet, Feng Che Kuan, Teresa Macarulla, Filippo Pietrantonio, Rui Hua Xu, Hiroya Taniguchi, Thomas Winder, Satoshi Yuki, Shan Zeng, Tanios Bekaii-Saab

Research output: Contribution to journalReview articlepeer-review


Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician–patient communication points to facilitate shared decision-making.

Original languageEnglish (US)
JournalTherapeutic Advances in Medical Oncology
StatePublished - 2020


  • adverse events
  • metastatic colorectal cancer
  • practical management
  • regorafenib
  • third line

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Practical considerations in the use of regorafenib in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this